Do you want to read an article? Please log in or register.
Identifying advanced stage NSCLC patients who benefit from afatinib therapy using 18F-afatinib PET/CT imaging
Lung Cancer
RECOMMENDED
Related content
RECOMMENDED
Lung Cancer
The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Vekens K, Everaert H, Neyns B, Ilsen B, Decoster L
doi: 10.1016/j.cllc.2021.03.001
RECOMMENDED
Lung Cancer
Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Lancet Oncol.
Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, Küsters A, Tosch M, Hehr T, Eschmann SM, Bultel YP, Hass P, Fleckenstein J, Thieme A, Stockinger M, Dieckmann K, Miederer M, Holl G, Rischke HC, Gkika E, Adebahr S, König J, Grosu AL, PET-Plan study group
doi: 10.1016/S1470-2045(20)30013-9.
Lung Cancer
Application of clinical trial inclusion criteria to clinical practice patients to quantify the burden of CNS metastases on health-related quality of life and healthcare resource use in patients with NSCLC
Lung Cancer.
Crane G, Smoljanovic V, Khan N, Gally S, Tomasini P, Lara N, Gondos A, Hammerschmidt S
doi: 10.1016/j.lungcan.
RECOMMENDED
Lung Cancer
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Mountzios G, de Toma A, Economopoulou P, Friedlaender A, Banini M, Lo Russo G, Baxevanos P, Roila F, Banna GL, Christopoulou A, Jimenez B, Collazo-Lorduy A, Linardou H, Calles A, Galetta D, Addeo A, Camerini A, Pizzutilo P, Kosmidis P, Garassino MC, Proto C, Signorelli D, Metro G
doi: 10.1016/j.cllc.2020.09.017
Sleep Apnea
Assessment of atherosclerotic plaque activity in patients with sleep apnea using hybrid positron emission tomography/magnetic resonance imaging (PET/MRI): a feasibility study
Sleep Breath.
Kundel V, Trivieri MG, Karakatsanis NA, Robson PM, Mani V, Kizer JR, Kaplan R, Fayad Z, Shah N
doi: 10.1007/s11325-018-1646-2.
RECOMMENDED
Lung Cancer
Variation between multidisciplinary tumor boards in clinical staging and treatment recommendations for patients with locally advanced non-small cell lung cancer
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Hoeijmakers F, Heineman DJ, Daniels JM, Beck N, Tollenaar RAEM, Wouters MWJM, Marang-van de Mheen PJ, Schreurs WH, MDT study group
doi: 10.1016/j.chest.2020.07.054.
Lung Cancer
Durvalumab consolidation therapy in a patient with stage IIIB unresectable NSCLC harboring a MET exon 14 splice site alteration
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Cytryn S, Ferreira V, Boland P, Chachoua A, Sabari J
doi: 10.1016/j.lungcan.2021.05.033
RECOMMENDED
Lung Cancer
Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR+ and ALK+ Positive Non-small-cell Lung Cancer Treated in the Real-World
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Goulart BHL, Chennupati S, Fedorenko CR, Ramsey SD
doi: 10.1016/j.cllc.2021.01.019
RECOMMENDED
Lung Cancer
Prospective trial of immuno(chemo)therapy before resection, definitive chemoradiotherapy or palliative therapy in patients with locally advanced or oligometastatic non-small cell lung cancer without a primary curative option
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Eur J Cancer
Faehling M, Fallscheer S, Kramberg S, Sträter J, Eschmann S, Sätzler R, Heinzelmann F
doi: 10.1016/j.ejca.2021.07.035